About Us

Dexorgen, Inc. is an advanced biotechnology company headquartered in the state of Maryland. We offer simple and high throughput solutions to aid scientists in solving complex problems. One of our primary focuses is on drug discovery. We are a leader in providing live cell based assays for novel compound screening. Our patented ACTOne based phosphodiesterase (PDE) and G-protein coupled receptor (GPCR) cell lines offer clients the ability to conduct efficient screenings of new compounds in a physiologically accurate, live cell based environment. We are the first in the world to produce commercially available cell lines to screen for compounds that target PDEs. We also provide a number of unique biochemical assay kits and specialty dyes. We strive to deliver high quality products that help our fellow scientists in the discovery process.

In the past five years, Dexorgen participated in Tox21, a federal collaboration involving the NIH, EPA and FDA. We developed assays for nuclear hormone receptors, dye based mitochondria toxicity assays. Now, we are developing the assays to evaluate the toxicities on TSHR and TRHR.

Dexorgen provides cell based assay products and services to academic and governmental research institutes, pharmaceutical and biotechnology industry. The company is headquartered in the I-270 Hi-Tech corridor in the state of Maryland. The core products of Dexorgen are ACTOne Cell lines and membrane potential kits which are licensed from BD Biosciences. We also develop new cell based products to meet the demands from various customers.